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 Group A Streptococcus (GAS) is responsible for mild and common 
infections like tonsillitis and pharyngitis, and more serious invasive disorders like 
necrotizing fasciitis and glomerulonephritis.  The ability to invade tissues is 
closely linked to the virulence factors expressed by the bacterium. Hyaluronic 
acid capsule expression is variable among all the strains in S. pyogenes and 
confers the capacity to evade the immune response. In a previous study, it was 
found that capsule production in CovR mutants was temperature-regulated, 
showing no capsule production at 37℃ but increased production was observed 
at 25℃. In this study, the objective is to find the elements involved in the 
thermoregulation using a genetic approach. First, mutants were created by 
knocking-out CovR, the response regulator of the CovRS two-component system 
that controls about 15% of GAS genome. Transposon mutants were screened to 
find changes in capsular phenotype. Colonies expressing capsule at 37℃ were 
selected for sequencing. The sequencing revealed three different events in 
different mutants. Two of them pointed at hypothetical proteins, one of them, 
i
SpyM3_1255, was phage associated protein with a DnaD domain and the other 
one, SpyM3_1377, encoded cvfA. A third over-producer mutant showed an 
insertion in the promoter area of the has operon, the operon that encodes for 
hyaluronan synthase production, upstream from other disruptions in the promoter 
area that generated non-producing mutants. This suggest that there is more than 
one factor involved in thermoregulation of capsule production.
ii
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 Streptococcus pyogenes is a Gram positive human pathogen that grows in 
chains (Figure 1) and is the causative agent of relatively mild diseases such as 
tonsillitis, pharyngitis, pyoderma and impetigo or serious invasive infections like 
necrotizing fasciitis and streptococcal toxic shock syndrome. In some cases, after 
infection with Group A Streptococcus (GAS) post-streptococcal systemic 
diseases like rheumatic fever, glomerulonephritis, endocarditis (91) and 
Sydenhamʼs chorea (56) could develop.  S. pyogenes can be found naturally in 
the human skin and throat. It is an aerotolerant anaerobe called β-hemolytic 
because of the complete hemolysis pattern formed in blood agar (β-hemolysis) 
(67). 
In the United States, each year there are over 10,000 cases of invasive 
streptococcus infections such as necrotizing fasciitis, bacteremia and toxic shock 
syndrome, resulting in 1,000 – 1,800 deaths (76).
Global epidemiology is unknown due to poor report and surveillance 
systems in most developing countries. However, it is estimated that there are at 
least 517,000 deaths each year linked to severe streptococcal infections and 
post-streptococcal diseases. The prevalence of GAS is at least 18.1 million cases 
with 1.78 million new cases each year (13) and there are at least 663,000 new 
cases with 163,000 deaths each year from invasive GAS infections. That added 
to the fact that there are more than 111 million cases of pyoderma and 616 
1
million cases of pharyngitis per year, it is easy to conclude that there is a high 
prevalence of streptococcal diseases in the clinical practice. 
Rebecca Lancefield, in 1928, published a method to serotype 
streptococcus based on its M protein, resulting in over 100 serotypes (59). Later, 
in 1946, she published another serotyping method based on the T protein, 20 
serotypes are known in this system (60), and 4 of the antigens related to T 
protein are pili, a structure relevant to attachment to host cells (75).
Pathogenesis and virulence factors of S. pyogenes
 There are several virulence factors in S. pyogenes that enable the 
bacterium to attach to host cells, invade deep tissues favoring spreading and 
avoid immune responses. Among those is the hyaluronic acid capsule which is 
the subject of this research and will be discussed in detail later. 
M protein, which is a major factor in phagocytosis evasion uses its ability to bind 
two different components of the immune response (C4BP and IgA) inhibiting 
opsonization and phagocytosis (14). It is also related to the autoimmune 
response in rheumatic fever and rheumatic heart disease derived from post-
streptococcal infection by eliciting a molecular mimicry mechanism and activating 
opsonic antibodies and lymphocytes (42). Another relevant characteristic of the 
well studied M protein is its interaction with peptides derived from the fifth domain 
of beta-2 glycoprotein I (beta-2-GPI), a human heparin binding plasma protein, 
which has antibacterial activities against Gram-positive and Gram-negative 
bacteria. Also, protein H and M1 protein, released from the bacterial cell wall by 
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FIGURE 1: Photomicrograph of Streptococcus bacteria, 900x magnification, 
showing its typical spherical shape and chain growth. (CDC Public Health Image 
Library). http://phil.cdc.gov/phil/details.asp
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polymorphonuclear-derived proteases, bind to, and inhibit the activity of, 
beta(2)GPI-derived antibacterial peptides. Taken together, it is suggested that the 
interaction between the streptococcal proteins and beta(2)GPI or beta(2)GPI-
derived peptides presents a novel mechanism to resist an antibacterial attack by 
beta(2)GPI-cleavage products (77).
 Another virulence factor is F protein, which facilitates adherence to host 
cells (9), and is linked to severe soft tissue infections (80). It also mediates 
invasion in HeLa cells and enables the bacteria to be internalized, proving that M 
protein is essential for adhesion, but F protein is essential for internalization (82). 
F protein shall not be confused with streptococcal pyrogenic exotoxin SpeF, 
previously referred as mitogenic factor, which, in Toxic Shock-like Syndrome 
caused by Streptococcus, causes permeabilization of lung vessels, leading to 
Acute Respiration Distress Syndrome (70). Moreover, F protein has 
superantigenic properties. Fibronectin-binding properties of S. pyogenes are also 
mediated by protein F (50). While M protein of S. pyogenes mediates the binding 
of the bacterium to keratinocytes, protein F directs the adherence of the 
organism to Langerhans' cells (81).
 Many of the virulence factors of GAS are not present in all clinical 
isolates, however, Streptolysin O (SLO), an oxygen-labile (thiol-activated) 
cytolysin, is present in most and is a powerful toxin that is partially responsible for 
hemolytic pattern and is highly cardiotoxic (49, 46). When absent, S. pyogenes 
shows a significant decrease in lethality and ability to cause disease (63). A 
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recent study found this pore-forming cytolytic streptolysin O as responsible and 
sufficient for apoptosis induction of macrophages and neutrophils involving 
caspase-1. This requires internalization of the bacterium by the phagocyte, 
contributing to GAS virulence and immune evasion (102). This toxin has the 
potential to establish a novel class of suicide gene therapeutic reagents (114). 
Membrane damage by SLO is analogous to that mediated by previously studied 
channel formers, namely, the C5b-9 complement complex and staphylococcal 
alpha-toxin (8). On capsule production, capsular and acapsular M3 strains were 
tested and the result was that the cytotoxic effects of streptolysin O protect GAS 
from phagocytic killing and enhance bacterial virulence, particularly of strains that 
may be relatively deficient in hyaluronic acid capsule (96). 
Another key virulence factor is streptolysin S (SLS), that is partially 
responsible, along with SLO, for the beta-hemolytic phenotype. It is encoded by 
the sagA gene (28). Despite a long time since its discovery, its chemical structure 
remains unknown (74).  SLS is not immunogenic; thus, no neutralizing antibodies 
are evoked during the course of natural infection, but recently, a synthetic peptide 
containing aminoacids 10 to 30 from the sagA gene coupled with keyhole limpet 
hemocyanin elicited an antibody response in a rabbit and reversed the hemolytic 
phenotype, giving cues to develop a new vaccine (28). 
GAS also secretes streptokinase which binds and activates plasminogen 
(7), the enzyme that destroys fibrin clots. Interactions between bacteria, 
fibrinogen, streptokinase and plasminogen resulted in acquisition of cell-
associated enzymatic activity that can lyse fibrin clots despite the presence of the 
5
major physiological plasmin inhibitor, alpha 2-antiplasmin (107), and this 
interaction promotes bacterial invasion of tissues (101). It is strongly believed 
that streptokinase plays a mayor role in acute post-streptococcal 
glomerulonephritis by initiating the nephritis process by glomerular deposition, 
which leads to local activation of the complement cascade. Detection of 
streptokinase in kidney tissue increased with the degree of glomerular 
hypercellularity. Thus, the severity of the pathological process may be a reflection 
of the degree of streptokinase deposition (78, 79).
Virtually all strains of the human bacterial pathogen Streptococcus 
pyogenes express a highly conserved extracellular cysteine protease known as 
streptococcal pyrogenic exotoxin B (SpeB) (65) that is used by GAS to kill 
phagocytes, as demonstrated by Lukomski et al, where a mutant lacking 
expression of SpeB was unable to resist phagocytosis and subsequent 
dissemination (66). SpeB also affects directly the production of hyaluronic acid 
capsule, when inactivated, extracellular hyaluronic acid levels decreased (112). It 
also degrades IgG, IgM, IgA, IgD and IgE (23). The mechanism to inactivate IgG 
is by cleaving IgG into Fc and Fab fragments, therefore, increasing bacterial 
survival (24, 37). Another proposed mechanism of phagocytic evasion by SpeB is 
by mitochondrial damage to the polymorphonuclear cells at an early infectious 
stage (18).  As reviewed so far, SpeB cleaves or degrades host serum proteins 
such as human extracellular matrix, immunoglobulins, complement components, 
and even GAS surface and secreted proteins. Destruction of both host and 
6
bacterial proteins makes SpeB the key virulence factor in GAS pathogenesis 
(19).
To invade host tissues, S. pyogenes uses hyaluronidase as one of the 
many virulence factors involved in invasion and dissemination. This chromosomal 
and phage-associated enzyme degrades hyaluronic acid from host tissues and 
increase adherence to epithelial host cells (6). A recent study found that 
hyaluronidase digests tissue hyaluronic acid and facilitates spread of large 
molecules but is not sufficient to cause subcutaneous diffusion of bacteria or to 
affect lesion size (98). Along with hyaluronidase, GAS also produces hyaluronic 
acid for its capsule, and another interesting finding was that hyaluronidase is not 
sufficiently active to remove capsule during peak synthesis (98). 
Purpose of this Study
 Human pathogens are exposed to changes in the environmental 
conditions, such as temperature, osmolarity and pH. In order to survive, bacteria 
have to regulate their gene expression according to environmental factors and, 
thus, ensure a successful colonization that allows them to thrive in the highly 
hostile human body. 
Temperature is one of the most relevant environmental factors. Several 
thermoregulation studies have been done in other bacteria, demonstrating how 
differential gene expression may be temperature-dependent, especially in 
pathogenesis, where body temperature is a significant cue for the bacterium to 
start the virulence machinery. 
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In the specific case of Group A Streptococcus, where colonization of both 
skin surface and blood is possible, there must be a thermoregulation in the 
capsule production that allows the bacteria to switch from one place to another 
while evading phagocytosis and internalization. 
Also, the products of temperature-regulated genes with central roles in 
physiology and virulence could be targets for novel therapeutics or mutation to 
generate defined live attenuated vaccines.

Hyaluronic acid capsule structure and synthesis
The most relevant virulence factor for this study is the hyaluronic acid (HA) 
capsule produced in the surface of the bacterial cell that plays a key role in 
virulence and invasiveness in mucoid strains (109). The capsule is also a 
mechanism to avoid oxygen damage by isolating the cell from the environment, 
making oxygen diffusion through the capsule much more slow, providing the 
bacterium with a shield from oxygen metabolites (22). The virulence of HA 
capsule is derived from its capacity to confer phagocytosis resistance to the 
bacterium (110) and is not necessary to be heavily expressed to confer full 
virulence, as demonstrated by Ashbaugh, where moderately encapsulated 
strains and heavily encapsulated strains posed the same invasiveness and 
virulence (4). The capsule in Streptococcus pyogenes is also required for biofilm 
formation by helping in the process of maturation into a tridimensional structure 
(20)
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The composition of hyaluronic acid is shared by bacteria and mammalians 
alike, therefore the immune system is unable to recognize encapsulated bacteria 
leading to failed opsonization and phagocytosis (27).  Encapsulated strains are 
very invasive in soft tissue infections, as oppose to uncapsulated strains that are 
internalized by keratinocytes (93) resulting in a noninvasive disease, and 
evidencing the fact that in order to spread, GAS needs to avoid phagocytosis and 
internalization and this is accomplished by capsule production (30). Introduction 
of GAS into the pharynx or deep tissues activates capsule production in 
capsulated strains (44), however, the underlying mechanism remains unknown, 
although several putative environmental triggers have been studied with little 
success. In this regard, a recent publication tried to identify the trigger, after 
noticing how mucoid strains on primary culture lost their encapsulated phenotype 
after laboratory passage, suggesting that the trigger must be present in the host 
environment and absent in most laboratory culture media. They found that 
cathelicidin LL-37, a human antimicrobial, had the ability to stimulate CovRS-
regulated virulence factors (45).
HA is synthesized at the protoplast and its structure is a polymer of 
disaccharides, themselves composed of D-glucuronic acid and D-N-
acetylglucosamine, linked via alternating β-1,4 and β-1,3 glycosidic bonds. 
Hyaluronic acid can be 25,000 disaccharide repeats in length. Polymers of 
hyaluronan can range in size from 5,000 to 20,000,000 Da in vivo (99, 73, 100) 
(Figure 2). The average molecular weight of extracellular HA is 2 X 106, and its 
production is only effective until the cell reach stationary phase, where production 
9
is halted, possibly because of changes in membrane conformation (106). HA 
release after formation is mediated by an ABC transport system, coded adjacent 
to the HA synthase gene with a reading frame in opposite direction (84).
 Synthesis of hyaluronic acid requires much energy and takes a high 
percentage of sugar, therefore, the obvious advantages of its synthesis is not 
widespread among pathogenic bacteria. The enzyme responsible for hyaluronic 
acid synthesis is Hyaluronic Acid Synthase.  The gene encoding this enzyme was 
first discovered in 1993 from GAS (31) and after that, it has been described in 
different species in bacteria and mammals as well. These various hyaluronic acid 
synthases share many common features and aminoacid sequence regions 
identity or similarity (108). In Streptococcus pyogenes, the HA synthase is known 
as HAs Class I. 
The first work identifying the HA synthase was in 1950 by Dorfman. In his 
paper, he described the enzyme as membrane-bound that needed Mg++ and 
used two sugar-nucleotide substrates, uridine diphospho-glucuronic acid (UDP-
GlcA) and uridine diphospho-H-acetylglucosamine (UDP-GlcNAc) to polymerize 
a hyaluronic acid chain (69) adding one after another at the reducing end (103). 
Different from proteoglycans, hyaluronic acid chain initiation does not need a 
protein backbone, the sole presence of the nucleotide sugar precursors are 
enough to elicit initiation and elongation (84). 
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FIGURE 2: Structure of hyaluronic acid. Hyaluronic acid consists of repeating 
disaccharides composed of N-acetylglucosamine (GlcNAc) and glucuronic acid 
(GlcA). 
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HA synthase is very unique; it has two different functions as 
glycosyltransferase. The product of the first sugar addition is the substrate for the 
next addition (108). The overall reaction for the synthesis of one hyaluronan 
disaccharide unit is:
Although this reaction seems simple, it is believed that at least six different 
reactions take place to complete the cycle.  Before it is released, the chain can 
grow to more than 40,000 monosaccharides, corresponding to a mass of more 
than 8 million Da. The sugar-nucleotide substrates are produced and used by the 
synthase inside the cell, and the hyaluronan chain is continuously transferred 
(translocated) so that it is extruded into the exterior of the cell to form the capsule 
(Figure 3). It was also believed that in absence of precursors, capsule would not 
be able to be synthesized and that hyaluronidase may play a role in solving this 
problem. To demonstrate a possible nutritional role for hyaluronidase, GAS was 
shown to grow with N-acetylglucosamine but not d-glucuronic acid (both 
components of HA) as a sole carbon source. However, only hyaluronidase (+) 
strains could grow utilizing HA as a sole carbon source, suggesting that 
hyaluronidase may permit the organism to utilize host HA or its own capsule as 
an energy source (98).
As bacterial hyaluronic acid is very similar to human and other vertebrates 
molecule, different strains of Streptococcus is being use for production and later 
use for purpose of human health and cosmetic industry (113). Also recombinant 
12
FIGURE 3: Enzyme functions needed for hyaluronic acid biosynthesis. The 
diagram shows the membrane-bound hyaluronan synthase and the six 
independent activities required for the enzyme to make a disaccharide unit and 
extend the growing hyaluronic acid chain. (Image used with permission of 
Glycoforum. www.glycoforum.gr.jp).
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HA from E. coli (115), B. subtillis (111)  and Agrobacterium sp. (68) is used 
for commercial purposes. 
The hyaluronic acid synthesis (has) operon in Streptococcus species.
 Hyaluronic acid production is coded in an operon containing three genes: 
hasA, hasB, and hasC, which encode hyaluronan synthase, UDP-Glc 
dehydrogenase and UDP-Glc pyrophosphorylase, respectively (Figure 4).  hasA 
codes for the enzyme responsible for the overall hyaluronic acid synthesis 
reaction (35), hasB is necessary to make UDP-GlcA, one of the substrates 
needed for HA production, from UDP-Glc in an oxidation that requires 2 NAD+ 
(34), and hasC codes for the enzyme that creates UDP-Glc from UTP and Glc-1-
phosphate (25).  Deletion analysis of the operon by Ashbaugh demonstrated that 
hasC gene, although it is part of the transcript, is not necessary for hyaluronic 
acid production, therefore hasAB are the only genes necessary for capsule 
production (5) and probably the hasC function is shared by other metabolic 
pathways in the cell. This operon is quite unique for Streptococcal species and 
recent phylogenetic studies show that there is no evidence of detectable inter-
species lateral gene transfer suggesting intra-species genetic rearrangement as 
the origin of has operon (34). It also shows that the hasA is highly conserved 
among streptococcal strains, different from the M protein that is highly variable 
(32).  Even when all streptococcal strains posses the operon, not every strain 
have the capsular phenotype. In acapsular phenotype, no operon mRNA 
14
HAS OPERON: 3606 base pairs (bp)
 
hasA (1259 bp    hasB (1208 bp)   hasC (915 bp)    spyM3_1854       recF
FIGURE 4: General representation of has operon and its genomic context. The 
P represents the promoter area and the T is the terminator.
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P T
transcript is expressed (26). Further characterization of the operon showed a 
promoter consensus sequence upstream the hasA gene, and no terminator 
sequence was found on hasA, indicating that the has operon promoter could 
regulate transcription of the entire operon, thus producing a polycistronic mRNA 
(26), therefore, mutations in the has operon promoter or in the hasA gene lead to 
a polar effect.
The level of capsule production sometimes differs among individual strains 
of the same M-type. It is likely that strain-specific factors also affect capsule 
production along with the intrinsic strength of the has promoter conferred by the 
serotype-specific has promoter sequence (1). 
Streptococcus pyogenes gene regulation
 Gene regulation in Streptococcus pyogenes is mediated by several 
regulators that either activate or repress certain genes in response to growth 
phase or environmental triggers this is achieved by transcriptional regulator 
proteins, like Mga (12), a regulator of gene expression, which is responsible for 
the activation of expression during exponential growth of genes involved in 
adhesion, internalization and immune evasion and influences the expression of 
over 10% of all GAS genome, primarily genes and operons involved in 
metabolism and sugar utilization (53). Mga functions as a DNA-binding protein 
that interacts with sites both proximal and distal to the start of transcription for the 
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genes that it regulates (2). Ribardo et al  (89) described an open reading frame 
named amrA that is required for maximal activation of the Mga regulon during 
exponential phase and is strongly conserved across different streptococcal M 
types. Inactivation of amrA in an M3 serotype also resulted in reduction of the 
gene coding M protein, emm, transcripts, therefore, the role of amrA does not 
appear to be serotype specific. Although the specific function of AmrA is 
unknown, its putative membrane localization and homology to transporters 
involved in cell wall synthesis suggest a link between growth and Mga (89).  
Many virulence regulators in other bacteria respond to carbon catabolite 
repression, a potential catabolite-responsive element important for binding by the 
catabolite control protein A (CcpA) was found in the promoter area of Mga 
upstream of its distal P1 start of transcription, supporting the role for CcpA in the 
early activation of the Mga promoter and establishing a link between carbon 
catabolite repression and Mga regulation in GAS (3). A link in a regulatory 
pathway has been found between CovRS and Mga, this is mediated by a novel 
two-component system regulator, which is CovR repressed, named TrxR that 
regulates the expression of Mga regulon genes, therefore, connecting CovR 
expression with Mga, affecting pathogenesis in GAS (61).
 Gene regulation in S. pyogenes is also achieved by two-component 
systems like CovRS, the global response regulator that mediates expression of 
about 15% of all GAS genome (43). 
 Two-component regulatory systems constitute an extensive superfamily of 
pairs of functionally linked proteins that modulate the activity of biochemical 
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pathways and regulate the expression of virulence factors in many bacteria. The 
sensor component typically consists of a membrane-bound protein that responds 
to an environmental signal by phosphorylating a conserved histidine residue in a 
cytoplasmic transmitter domain of the sensor protein. The phosphate group is 
subsequently transferred from the sensor protein to a conserved aspartic acid 
residue in the receiver domain of the response regulator, a cytoplasmic protein. 
Regulator proteins of this type influence expression of target genes by acting as 
transcriptional activators or repressors, and their activity at binding sites 
upstream of target genes depends upon the phosphorylation state of the protein. 
Phosphorylation alters the DNA binding properties of the response protein 
regarding either affinity or target specificity.
 Levin and Wessels described the effect of the system on hyaluronic acid 
capsule production and named the system csrRS for “capsule synthesis 
regulator” and found that csrR was the negative response regulator and csrS was 
the sensor component and are very conserved among Streptococcus (62).  
Federle found five different sites of CovR binding to the has operon promoter 
area and concluded that, except for the almost overlapping binding site pair CB-1 
and -2, binding of CovR to each of the five sites surrounding the hasA promoter 
is independent of binding at the other sites. However, binding at all of these sites 
is needed for complete repression of this promoter in vivo (38).  
 CovRS protein products are members of the OmpR/EnvZ two-component 
signal transduction family (29). It is widely accepted that CovS mediates CovR 
phosphorylation, however, further studies gave evidence that in some 
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exceptional cases CovS may not be needed for CovR phosphorylation and 
consequent activation, even when these two proteins are cotranscribed, there 
could be another element in the cell able to phosphorylate CovR in absence of 
CovS (29). Phosphorylation of CovR by acetyl phosphate results in dimerization 
(48) significantly enhancing repression of one group of genes (e.g. speA, hasA, 
ska) while reducing repression of a second group (e.g. speB, grab, spd3) (105). 
CovS is required for growth under stress conditions like high temperature, 
high salt concentration and low pH (29).  CovRS has been described as a 
double-negative regulator, where CovR represses transcription of the covRS 
operon by promoter occlusion (47), so as long as CovR is active, very little new 
CovR protein is made. 
The consensus region of CovR binding at the promoter area of both covR 
and has operons is ATTARA, where R could be any purine. In this sequence the 
T residues key in CovR binding (40). Another consequence of stress-induced 
inactivation of CovR is derepression of CovR synthesis. It can be expected that 
under stress conditions, more inactive CovR accumulates so that when stress is 
relieved and CovR becomes active, there is a rapid repression response. The 
design of this system thus makes it very sensitive to environmental change, like 
temperature. Since CovR-regulated promoters may vary in their degrees of 
sensitivity to CovR phosphorylation, CovR-regulated genes may exhibit 
differential expression under both normal and stress conditions and may respond 
to various degrees when the GAS encounters stress conditions (29). 
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CovR is also regulated by RocA, named for “regulator of Cov”, which plays 
an important role in regulation of the operon by increasing its expression and 
activation of covR transcription is increased about threefold. As expected, a rocA 
mutant is mucoid and produces more transcript from the has promoter since this 
promoter is repressed by CovR. This regulator is present in GAS but not in other 
species like Group B Streptococcus or Group G Streptococcus (10).
  There are other regulators than the previously described CovRS and 
Mga. For instance, the RofA-like proteins (RALP) including RofA and Nra (39), 
regulate genes involved in persistence; FasA, which is involved in growth phase 
regulation of virulence gene expression (58) and Rgg (RopB), which activates 
expression of extracellular proteins such as SpeB (16). Rgg has also been 
shown to play a role in regulating the metabolic activities of GAS (17).
Thermoregulation in bacterial gene expression
Temperature is a relevant stress factor sensed by bacteria and used to 
regulate gene expression. Depending on the induction mechanism, two different 
pathways have to be distinguished, namely the heat shock response and the 
high temperature response. While the heat shock response is induced by 
temperature increments and is transient, the high temperature response needs a 
specific temperature to become induced and proceeds as long as cells are 
exposed to that temperature. The heat shock response is induced by denatured 
proteins and aimed to prevent definitive denaturation and formation of protein 
aggregates by refolding, and the high temperature response is mainly used by 
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pathogenic bacteria to detect entry into a mammalian host followed by induction 
of their virulence genes (94). Thus, thermoregulation in gene expression has 
been described in several bacterial species. Several pathogenic bacteria 
undergo temperature shift when going from one host to another or from one 
environment to another, e.g. skin to deep tissues. Genes are up or down-
regulated depending on different temperatures; this difference, in some cases, 
has been linked to promoter sequence, as for maRAB and acrAB in Salmonella 
thyphimurium (51). Another report on Salmonella found a strong thermosensing 
for virulence phenotype where bacteria grown at 30℃ or lower were unable to 
activate the intracellular type III secretion system even under strong inducing 
signals such as synthetic medium, contact with macrophages, and exposure to 
the murine gut (36). 
Three different macromolecules have been identified being able to sense 
temperature: DNA, proteins and mRNA. For example, DNA supercoiling can 
control gene expression of pVY virulence plasmid in Yersinia enterocolítica (90) 
as well as virB expression in Shigella (87). Protein regulation that are 
temperature-dependent are found in the expression of flagella gene in Listeria 
species (95) and the two-component signal transduction BvgAS in Bordetella 
pertussis (55). RNA regulation is conferred by riboswitches and an example is 
the LcrF production in Yersinia pestis (52) that induces expression of several 
virulence factors. An example of how temperature regulates the expression of a 
two-component signal transduction is BvgSR in Bordetella pertussis, the 
causative agent of whooping cough (57). This system is transcribed and up-
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regulated at 37°C and down-regulated at 25°C (88) and the mechanism is very 
similar to CovR activation by phophorylation (55). Microarray studies with 
Francisella tularensis showed that after shifting temperature from 26°C to 37°C 
about 11% of the bacteriumʼs genes were differentially regulated and 40% of 
those genes are linked to pathogenesis (54). In group B streptococcus (GBS) 
changes in the genome occurred after incubation in blood at a temperature 
similar to those in patients with infection (about 40°C) (72), proving adaptative 
changes mediated by temperature in response to invasive infection. In a recent 
study in E. coli the effect of temperature on colicin K production was investigated 
and the results showed that expression was higher at 37°C than at 22°C and is 
hypothesized that SOS response indirectly regulates thermoregulation of colicin 
K (11). Another example of bacteria that uses temperature as a regulatory cue for 
pathogenicity is Borrelia burgdorferi, the causative agent of Lyme disease. It 
regulates expression of RevA in response to temperature, with the protein being 
synthesized by bacteria cultivated at 34℃ but not by those grown at 23℃ (15). 
In some cases, a change in DNA topology, instead of promoter sequence, can 
lead to thermoregulation, as reported for virB transcription in Shigella flexneri, 
where a reduction in negative superhelicity at the promoter area was identified 
(104).  
 As for Streptococcus pyogenes, previous studies have related some gene 
expression and temperature. At least 9% of the genes are expressed 
differentially at 29°C relative to 37°C, as shown in microarray analysis. These 
genes include transporter proteins, proteins involved in iron homeostasis, 
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transcriptional regulators, phage-associated proteins, and proteins with no known 
homologue. Relatively few known virulence genes were differentially expressed 
at this threshold (97). However, at 40°C more gene expression was shifted, 
showing that there is thermoregulation in gene expression in GAS.
Research Aims
  The aim of this study was to identify the gene(s) or protein(s) responsible 
for thermoregulation and which areas of the has operon promoter are involved. 
For this purpose transposon mutagenesis was performed. 
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MATERIALS AND METHODS
Media, Solutions and Standard Protocols
 All the recipes for media, buffers and solutions used in this research are 
provided in Appendix A. The protocols are described in Appendix B. 
Bacterial Strains and Plasmids
 The bacterial strains used in this research and their relevant 
characteristics are described in Table 1. Plasmid vectors are listed in Table 2.  
Molecular cloning experiments were performed with Top10 E. coli cells (64) which 
were cultured in Luria-Bertani broth at 37°C with agitation at 250 rpm. For routine 
culture of S. pyogenes, Todd-Hewitt medium (BBL) supplemented with 0.2% 
yeast extract (Difco) (THY medium) was employed. For growth in liquid media, S. 
pyogenes was cultured at 37°C in sealed tubes without agitation. To produce 
solid media, Bacto agar (Difco) was added to a final concentration of 1.4% (wt/
vol). When appropriate, antibiotics were added to the media (see Appendix A).
Plasmid construction
 The plasmids used in this work are listed in Table 2. Gene manipulation 
and cloning were carried out according to standard protocols (Sambrook et al, 
1989). Plasmid constructs were verified by PCR and gel electrophoresis. 
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Creation of CovR mutants
 CovR is the response regulator in the CovRS two-component system that 
regulates capsule expression. CovR mutants were created by two methods. One 
was an insertional disruption on the covR gene that was achieved by using 
pSpc18 vector that confers spectinomycin resistance. The plasmid is a 2.94 kb 
suicide vector with a multicloning site and an origin of replication for E. coli. A 
fragment of the covR gene was inserted to create the disruption in the target loci 
of the chromosome. Also, an in-frame deletion mutant was created using the 
temperature induced plasmid pJRS233; no resistance is conferred after plasmid 
excision. Both transformations were performed as described in Appendix B. 
Transposon mutagenesis
 Electroporation was performed to introduce the transposon into competent 
S. pyogenes cells prepared as described in Appendix B. Mutants were plated in 
THY plates with the appropriate antibiotic and incubated at 37°C as described in 
standard methods (21). Transformants with insertions of pMGC8, a plasmid 
carrying a transposon, were then recovered following overnight incubation at 
37°C on THY medium plates supplemented with kanamycin. Insertion was 
confirmed with PCR. For mutants displaying the desired phenotypes 
(overproducers or non-producers) the transposon insertion site was identified by 
chromosomal DNA sequencing. The strain used for transposon mutagenesis was 
CovRIFD which does not produce capsule at 37°C but produces it at 25°C.
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Capsule quantitation assay
 As different strains expressed capsule differently, a method to measure 
the amount of capsule was developed and optimized using Stains-all reagent; the 
complete protocol can be found in Appendix B. Stains-all is known to bind to acid 
polysaccharides. As hyaluronic acid is a highly acidic polysaccharide, Stains-all 
was used to quantitate the capsule amount produced by cells. The 
spectrophotometric readings were done using a 640 nm wavelength.   The first 
method included a resuspension of THY medium pellet along with the colony to 
be measured. This method was discontinued because the media caused 
interference with the spectrophotometer readings. The new method included only 
the colony in the resuspension. Another problem was the continuous growth of 
cells when incubating at room temperature for 24 hrs after the initial 37℃ 
incubation. To solve this problem, readings were done the same day using 
different sets of cells for each temperature to be measured. 
 A standard curve was created by measuring the absorbance of hyaluronic 
acid concentrations from 1 to 5 µL at 640 nm wavelength. The values obtained 
were plotted. The X axis represents optical density and Y axis the hyaluronic acid 
concentration. This generated an Y/X slope that was used to multiply the OD of 
the samples, the resulting number was then multiplied considering the dilution 
factor, which in this case was 2. The subsequent value was divided between the 
total cell number of the colonies and the result was converted from µg/cfu to fg/
cfu. All samples were duplicated and the values were averaged.
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TABLE 1: Bacterial Strains
Bacterial strains Relevant characteristics           Source




      HSC5
      OPTM18
      
      
      OPTM 2
      OPTM7
      ΩCovR
      
      CovRIFD
       MGAS315
      MGAS315ΩCovR
Wild type, M14 serotype
Transposon generated mutant 
with a disruption in has operon 
promoter area created with 
pMGC8. Overproducer 
phenotype
Transposon mutant with a 
disruption in a hypothetical 
protein created by pMGC8. 
Over-producer phenotype
Transposon mutant with a 
disruption in a hypothetical 
protein created by pMGC8. 
Overproducer phenotype.
HSC5 with a mutation in the 
covR gene created with 
pSPC18
HSC5 with an in-frame deletion 
in the covR gene created with 
pJRS233
Wild type
MGAS315 with an in-frame 


















Transposon containing km gene 
that confers kanamycin 
resistance.
Temperature-sensitive shuttle 
vector. Confers erythromycin 
resistance.
pUC18-based suicide vector 
containing aad9 (spectinomycin 
resistance gene from 
Enterococcus faecalis).
pUC18-based streptococcal 
integration vector; contains 
aphA3 conferring
kanamycin resistance
Self replicating plasmid. Confers 









Wild types and the generation of CovR mutants
 One of the wild type strains used in this study was the non-mucoid HSC5, 
which shows no capsule production at any temperature. To study the 
thermoregulation of capsule production, CovR, the response regulator of the 
CovRS two-component system was mutated, conferring a less regulated capsule 
expression with an obvious temperature-dependent production. The CovR 
mutants presented a clear temperature-dependent phenotype where no capsule 
was produced at 37℃ and there was capsule production after incubation at 25℃ 
(Figure 5). Because HSC5 is not fully sequenced, MGAS315 was used for 
genomic and phenotypical comparison. It showed the same non-mucoid 
phenotype as HSC5.
 To generate ΩCovR, the wild type was transformed with pSPC18, a 
plasmid carrying spectinomycin resistance that creates a disruption and partial 
duplication.
 An in-frame deletion CovR mutant was also created using the temperature 
regulated plasmid pJRS233 carrying erythromycin resistance. The resulting 
phenotype was similar to the ΩCovR mutant. For transposon mutagenesis 
experiments, this was the strain used because the in-frame deletion generates 
no partial duplicates, as opposed to insertional disruption (Figures 25 and 26). 
And because no double antibiotic resistance genes are carried (for each plasmid 
insertion).
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 HSC5, MGAS315 and CovR mutant strains showed a low capsule reading 
at 37℃, around 40 - 130 fg/μL. The difference in capsule production between 
37℃ and 25℃ was not significant, showing always low values. However, 
MGAS315 wild type usually had a higher values in capsule quantitation, 
compared to HSC5, but macroscopically, it showed no characteristic coat of 
hyaluronic acid, but only slightly larger colonies. For CovR mutants, the 
difference was significant (Tables 3-5) showing an increased production of 
hyaluronic acid capsule at 25℃ (Figures 6-9). Only in one measurement, HSC5 
showed capsule production (Tables 6-8, Figures 10-13) but further attempts to 
obtain the same phenotype failed, suggesting that the capsule production 
observed in HSC5 was a consequence of a technical or human error. 
 Measurements at 30℃ were performed to determine if there was an 
intermediate phenotype at an intermediate temperature. The results for this 
reading showed that CovR mutants start their capsule production slowly after 
removal from the 37℃ environment. 
CovRS complementation
 The phenotype of CovR mutants shows a temperature dependent capsule 
expression. To rule out a possible secondary mutation causing the phenotype a 
complementation experiment was performed. The plasmid used was pLZ12 
containing a fragment of the CovRS two-component system. After 
electroporation, revertants were obtained, showing the same phenotype 
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observed in the wild type. Capsule quantitation assay demonstrated a lack of 
capsule production in the complementation mutants (Tables 9-11, Figures 14-17). 
Temperature dependence of capsule expression
 The mutant strains ΩCovR and CovRIFD showed a temperature-
dependent expression of capsule. At 37℃, the strain showed no hyaluronic acid 
production, but at 25℃ an evident coat of hyaluronic acid capsule was produced 
(Figure 5).  In order to study the temperature dependence in HSC5, capsule 
measurements at 30℃ were performed. It was observed that the amount of 
capsule produced at this intermediate temperature was lower than the amount 
produced at 25℃, but higher than the amount at 37℃ (Tables 4, 7 and 10.  
Figures 7, 11 and 15 ).  
Transformation of MGAS315
 The strain used in this study, HSC5, is not fully sequenced and in order to 
have genomic profiles of the disrupted genes we used the sequence of 
MGAS315, a strain with the closest similarity to HSC5. The capsular phenotype 
of MGAS315 was the same as HSC5. An ΩCovR mutant using MGAS315 was 
created and the phenotype corresponded to that of the ΩCovR mutant with 
HSC5 background. Capsule quantitation assays showed only a slight increment 
in capsule amount (Tables 3-5), but the thermoregulated pattern of the MGAS315 
CovR mutant was maintained (Figures 6-9).
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    a)          b)    
      c) 
FIGURE 5: Capsule phenotype. a) no capsule production. b) and c) capsule 
production.
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HSC5-1 0.017 720,000 140.90
HSC5-2 0.018 730,000 147.14 144.02 4.41
MGAS315-1 0.020 700,000 170.50
MGAS315-2 0.020 780,000 153.01 161.75 12.36
ΩCovR-1 0.023 396,000 301.38
ΩCovR-2 0.021 394,000 257.48 279.43 31.04
MGAS315ΩCovR-1 0.020 480,000 285.94
MGAS315ΩCovR-2 0.017 500,000 250.63 268.28 24.96
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HSC5-1 0.020 440,000 264.51
HSC5-2 0.020 430,000 270.66 267.58 4.34
MGAS315-1 0.030 480,000 363.70
MGAS315-2 0.030 510,000 342.31 353.00 15.12
ΩCovR-1 0.100 244,000 2384.92
ΩCovR-2 0.090 236,000 2219.19 2302.05 117.18
MGAS315ΩCovR-1 0.120 370,000 1887.31
MGAS315ΩCovR-2 0.110 330,000 1939.73 1913.52 37.07
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HSC5-1 0.05 3,600,000 80.82
HSC5-2 0.05 3,700,000 78.64 79.73 1.54
MGAS315-1 0.04 3,300,000 70.54
MGAS315-2 0.04 3,200,000 72.74 71.64 1.55
ΩCovR-1 0.15 350,000 2,493.94
ΩCovR-2 0.13 33,000 2,292.41 2,393.18 142.50
MGAS315ΩCovR-1 0.09 180,000 2,909.60
MGAS315ΩCovR-2 0.09 190,000 2,756.46 2,833.03 108.28
35
FIGURE 6: Capsule quantitation of wild types and CovR mutants at 37℃.
FIGURE 7: Capsule quantitation of wild types and CovR mutants at 30℃. Note 
the different capsule amount in the CovR mutants, showing that in those strains 
















FIGURE 8: Capsule quantitation of wild types and CovR mutants at 25℃. 
FIGURE 9: Effect of temperature in wild type and CovR mutants. Note how CovR 

























conc (fg/cfu) Average Standard deviation
HSC5-1 0.004 4,000,000 58.09
HSC5-2 0.004 4,500,000 51.63 54.86 4.56
CovRIFD-1 0.004 6,500,000 35.75
CovRIFD-2 0.005 6,600,000 44.00 39.87 5.84
ΩCovR-1 0.005 7,800,000 37.23
ΩCovR-2 0.005 7,900,000 36.768 37.00 0.33
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HSC5-1 0.05 1,170,000 251.08
HSC5-2 0.04 1,090,000 215.60 233.34 25.08
CovRIFD-1 0.09 1,370,000 385.96
CovRIFD-2 0.07 1,280,000 321.30 353.63 45.72
ΩCovR-1 0.10 2,070,000 283.83
ΩCovR-2 0.09 1,970,000 268.41 276.12 10.90
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HSC5-1 0.17 1,270,000 786.44
HSC5-2 0.18 1,350,000 783.36 784.90 2.18
CovRIFD-1 0.18 1,590,000 665.12
CovRIFD-2 0.17 1,470,000 679.44 672.28 10.13
ΩCovR-1 0.20 1,670,000 703.62
ΩCovR-2 0.22 1,600,000 807.84 755.73 73.69
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FIGURE 10: Capsule quantitation of HSC5 and CovR mutants at 37℃.
















FIGURE 12: Capsule quantitation of HSC5 and CovR mutants at 25℃.
FIGURE 13: Effect of temperature on HSC5 and CovR mutants. Note that HSC5 




























HSC5-1 0.003 422,000 45.97
HSC5-2 0.003 427,000 45.43 45.70 0.38
ΩCovR-1 0.006 820,000 47.31
ΩCovR-2 0.007 1,030,000 43.94 45.63 2.38
ΩCovR(pCovRS)-1 0.005 820,000 39.43
ΩCovR(pCovRS)-2 0.006 860,000 45.11 42.27 4.01
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HSC5-1 0.006 730,000 47.05
HSC5-2 0.006 760,000 45.19 46.12 1.31
ΩCovR-1 0.177 1,790,000 566.06
ΩCovR-2 0.171 1,680,000 582.68 574.37 11.75
ΩCovR(pCovRS)-1 0.009 1,040,000 49.54
ΩCovR(pCovRS)-2 0.009 1,030,000 50.02 49.78 0.34
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conc (fg/cfu) Average Standard deviation
HSC5-1 0.008 1,030,000 44.46
HSC5-2 0.007 1,060,000 37.80 41.13 4.71
ΩCovR-1 0.240 2,070,000 663.72
ΩCovR-2 0.243 1,980,000 693.89 678.81 21.33
ΩCovR(pCovRS)-1 0.010 1,240,000 46.17
ΩCovR(pCovRS)-2 0.009 1,360,000 37.88 42.02 5.86
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FIGURE 14: Capsule quantitation for CovRS complementation strain and 
controls at 37℃. 

















FIGURE 16: Capsule quantitation for CovRS complementation strain and 
controls at 25℃.


















  The efficiency is expected to be high in this kind of experiments because 
the insertion is random and the mobile element is very stable. After 
electroporation and incubation, several mutants were screened and selected 
mutants showing anomalous capsule expression were tested for proper insertion 
and sequencing. The strain used in these experiments was CovRIFD. The 
capsular phenotypes observed in the transposon mutants were a) non-producer, 
which didnʼt produce capsule at room temperature, and b) overproducer that 
produced capsule at 37℃, as opposed to the background strain CovRIFD. 
Approximately 20 non-producer colonies were examined and all of them showed 
insertions in either hasA gene or hasA promoter area. Of particular interest were 
the overproducer phenotype, and those were sequenced to identify the disrupted 
area. The mutants were named OPTM for “overproducing transposon mutant”.
 The data obtained from the transposon mutagenesis experiments 
revealed more than one chromosomal location involved in the thermoregulation 
of capsule production and that a mutation in this system confers an increased 
capsule production at 37℃, thus, giving the potential of more virulence and 
invasiveness, adding more evidence to the fact that virulence regulation is 
complex in S. pyogenes and that it could respond to more than one molecular 
trigger.
 Four mutants with three different insertion sites that resulted in massive 
capsule expression at 37℃, were analyzed. The strains were called OPTM2, 
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OPTM7, OPTM17 and OPTM18. All were sequenced to obtain the insertion 
location. 
OPTM2
 The first mutant sequenced was named OPTM2. Blasting the sequence 
against an MGAS315 genomic database showed an insertion in the gene 
spyM3_1254 (Figure 18). There was a possibility that this disruption caused 
polarity effect on downstream genes and gave an overproducer phenotype. 
There are about 14 genes downstream of spyM3_1254 that are also hypothetical 
proteins encoding phage associated proteins whose products have not been well 
characterized. Inactivation in any of these genes by polar effect may lead to an 
overproducing phenotype from a gene different from the one disrupted.

OPTM7 and OPTM16
 Two other overproducers, OPTM7 and OPTM16 showed an insertion in 
the cvfA (spym3_1377) gene (Figure 19). Downstream of cvfA there is a gene 
encoding a guanylate kinase. CvfA is a predicted HD superfamily hydrolase that 
in previous studies it has been found to be linked to virulence in S. pyogenes, as 
well as virulence in B. subtillis and S. aureus (71). As part of the continued 
research, protein work is being performed in order to elucidate the possible 
interaction between cvfA and thermoregulation of capsule production. 
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OPTM18
 Another over-producer mutant, OPTM18, showed a different insertion site. 
Identification of the transposon insertion loci revealed that this mutant had an 
insertion in the intergenic area, upstream from the insertion site at the promoter 
area of hasA, found in non-producers (Figure 20).  
 There are five binding sites for CovR at the promoter area; none of these 
was affected by the transposon insertion, but this particular finding may imply 
that part of the sequence upstream from the promoter region of the has operon is 
involved in the thermoregulation in GAS, along with other elements found in the 
other mutants obtained in this study.
 Capsule was measured in mutants and wild type strains. OPTM18 showed 
an increment in capsule production at 37℃ compared with the wild type, 
reaching values higher than 900 fg/μL at 37℃ (Figures 21 and 22).
 However, insertional inactivation of the same promoter area region by site 












                                                                                                stop
GGAAGCATAGACGGTATAGAAGATGGATCAGGAGATTTTTAA
FIGURE 18: Complete sequence of spyM3_1254. The insertion site of the 

































                                                                                                                        stop
FIGURE 19: Partial sequence of spym3_1376, the cvfA gene. The gene is 1608 
nucleotides long. Here only the first 259 nucleotides are shown. The vertical 
arrows represent the insertion site of the transposon. Arrow “a” points the 







                                                                          ▼a
TATTTTTTCATAAAATTAGATAAAACTCTTGGAAAAGTTTACTAAAATAATTTATA
ACAATTCAATTATCCTGATTTTTCTTTTTTCGGGGGAATTTTTTTTATTGAAACA
                                                                          -35                 
CAATTTTATTAAAAATATCTCTATGTCTAGTTGACATTATTTCTTATTTATATTAG




FIGURE 20: The hasA promoter region. The start of hasA transcription is shown 
as +1. Promoter elements (-10 and -35 region) and the ribosome-binding site 
(RBS) are indicated in bold. 5ʼ-ends of hasA and spy_2199 are indicated by 
horizontal arrows. Five CovR binding sites are underlined. The two vertical 
arrows indicate transposon insertion sites showing opposite phenotypes. The 
transposon insertion close to the transcription start site (vertical arrow b) 
generated a capsule non-producer. The transposon insertion 178 bases 
upstream of the start codon (vertical arrow a) generated a capsule overproducer 
at 37˚C (OPTM18).
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MGAS315-1 0.004 340,000 85.95
MGAS315-2 0.005 420,000 86.97 86.46 0.72
MGAS315ΩCovR-1 0.006 470,000 93.27
MGAS315ΩCovR-2 0.006 440,000 99.62 96.45 4.50
OPTM2-1 0.648 4,600,000 1,029.16
OPTM2-2 0.618 4,100,000 1,101.22 1,065.19 50.95
OPTM7-1 0.547 4,800,000 832.56
OPTM7-2 0.532 4,300,000 903.88 868.22 50.43
OPTM18-1 0.597 4,600,000 948.17
OPTM18-2 0.666 4,200,000 1,158.49 1,053.33 148.72
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MGAS315-1 0.007 620,000 82.48
MGAS315-2 0.008 680,000 85.95 84.22 2.45
MGAS315ΩCovR-1 0.191 1690000 800.16
MGAS315ΩCovR-2 0.193 1650000 807.48 803.82 5.18
OPTM2-1 0.735 5,500,000 976.32
OPTM2-2 0.771 5,900,000 954.71 965.51 15.28
OPTM7-1 0.697 6,200,000 821.31
OPTM7-2 0.713 6,400,000 813.91 817.61 5.23
OPTM18-1 0.803 6,100,000 961.73
OPTM18-2 0.796 5,900,000 985.66 973.70 16.92
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    fg/cfu
FIGURE 21: Capsule production of transposon mutants at 37℃. Note the 
increased amount of capsule in transposon mutants.
      fg/cfu
FIGURE 22: Capsule production of transposon mutants at 25℃. Note how wild 
























































  Knock-out experiments were done for phenotype confirmation of 
OPTM18. The target promoter area was amplified by PCR (Table 14) and cloned 
into PCIV2, a 4.195 kb plasmid harboring kanamycin resistance. After 
transformation, the phenotype of the transformant was similar to the background 
strain, no capsule production at 37℃ and capsule production at 25℃. The 
insertion mechanism of insertional inactivation is different from transposon 
mutagenesis and this could explain the difference in phenotype. While PMGC8 
was inserted into the target using transposase (Figure 25), PCIV2 was integrated 
causing an insertional disruption with a fragment of the target gene, generating 
partial duplicates of certain target sequences that would be inactive (Figure 26) 
but this could generate a partial binding site or recognition sequence.
 The knock-out was confirmed using a confirmation primer that contains a 
sequence in the target gene area, OPhasAP-confirm, and a set of primers that 
anneal to the vector in two different sites in a reverse and forward direction, M13-
f and M13-r, respectively (Table 15).  The insertion is confirmed when  an 
amplicon of 782 bp is present in a PCR reaction with the confirmation primer and 
one of the M13 primers. In this experiment, bands were present with the M13-r 
set, showing a reverse direction insertion (Figures 23 and 24).
 However, knock-out experiments failed to mimic the same overproducer 
phenotype. This may be partially explained by the different insertion mechanisms 
for both, plasmid and transposon. While in transposon mutagenesis the 
continuity of the  DNA sequence is disrupted by the insertion of the mobile 
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element, in insertional disruption a partial duplication is created (figures 25 and 
26). 
 The influence of temperature in pathogen gene expression has been 
widely studied, and many thermoregulated genes are known. Several 
mechanisms are described in different species and specific genomic changes 
have been determined by microarray analysis in GAS, however, most of the 
differential expression revealed was in hypothetical proteins (97).
 The results presented in this study could throw some light upon the 
hypothetical function of uncharacterized proteins and help to develop a model of 
thermoregulation in S. pyogenes capsule production, leading to better 
understanding of virulence and physiology in this species.
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TABLE 14: PCR primers used for hasA promoter area amplification
   
Primer name Primer sequence
5OPhasASph 5ʼ - AAAAGCATGCTCTGTTTCTAGCATTCAAATGTC C - 3ʼ
3OPhasASph 5ʼ - AAAAGCATGCTCTGTTTCTAGCATTCAAATGTC C - 3ʼ
The first 4 As of the sequence are overhangs, GCATGCT is the recognition site 
of the restriction enzyme SphI. The optimum PCR condition for amplification of 
the hasA promoter area was 55℃ for annealing temperature and one minute of 
extension. 
TABLE 15: Primers used for hasA promoter area knock-out confirmation
Primer name Primer sequence
OPhasAP-confirm 5ʼ - TACTCCCTGAACAATTTTCATAATG - 3ʼ
M13 - f 5ʼ -CGCCAGGGTTTTCCCAGTCACGAC - 3ʼ
M13 - r 5ʼ - AGCGGATAACAATTTCACACAGGA - 3ʼ
The optimum PCR condition to check the right insertion was 52℃ of annealing 




                                      1        2        3       4        5       6       7
FIGURE 23: Gel electrophoresis of nucleic acids for knockout experiments. a) 
amplification of the promoter area of has operon. b) Bands confirming the 
insertion of PCIV2 in a reverse direction and consequent disruption of a region of 
the has operon promoter area.  Lanes 1-5 are transformation products. Lane 6 is 
a positive control and lane 7 is a negative control.
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782 bp
          CFhasA  M13-f                                                           
            
                                                                                
               M13-r
                                                                                                                                                         
FIGURE 24: Primer annealing for knock-out confirmation. The black bold lines 
represent the chromosome region of hasA. The grey line in between represents 
the inserted plasmid. The fine line below the chromosome with plasmid insertion 
is the extension obtained in this experiment, confirming a reverse insertion. The 
green rectangles are the primers in their annealing site.
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FIGURE 25: Graphic representation of transposon insertion. The green circles 
are transposase. The transposon is inserted randomly into the genome, causing 
a wide variety of mutations on each transformation, derived from gene disruption 
at the insertion site.
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FIGURE 26: Graphic representation of insertional inactivation. The plasmid is 
inserted into the chromosome by homologous recombination between a fragment 
of the target gene and the chromosomal target gene loci. The insertion creates a 
disrupted gene and a partial duplication of the target sequence.
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APPENDIX A: Media, Buffers and Solutions
I. Media
1) Luria-Bertani Broth (per liter):
10 grams  NaCl
10 grams  Tryptone (Fisher Scientific) 
5 grams  Yeast extract (Difco)
Adjust pH to 7.6 with NaOH solution.  Autoclave at 20 psi for 30 
minutes.
2) THY broth (per liter):
30 grams  Todd Hewitt (BBL)
2 grams  Yeast extract (Difco)
Autoclave at 20 psi for 30 minutes.
3) TP broth (per liter):
30 grams  Todd Hewitt (BBL)
2 grams  Yeast extract (Difco)
20 grams  Peptone (Bacto brand)
Autoclave at 20 psi for 30 minutes
83
4) THY agar plates (per liter, approximately 40 plates):
30 grams  Todd Hewitt
2 grams  Yeast extract
14 grams  Agar (Bacto brand)
Autoclave at 20 psi for 30 minutes. Let cool down to 55°C. Add 
appropriate antibiotic if needed before pouring plates. 
5) LB agar plates (per liter, approximately 40 plates):
10 grams  NaCl
10 grams   Tryptone
5 grams   Yeast extract
14 grams  Agar (Bacto brand)
Autoclave at 20 psi for 30 minutes. Let cool down to 55°C. Add 




Antibiotic AbbreviationSolvent Concentration 
of stock solution
Storage
Chloramphenicol Cam, Cm 50% EtOH 10 mg/ml 4°C
Erythromycin for 
E. coli
Erm, Em 100% EtOH 75 mg/ml 4°C
Erythromycin for
S. pyogenes
Erm, Em 100% EtOH 1 mg/ml 4°C
Kanamycin Kan, Kn ddH2O, filter 100 mg/ml 4°C





Volume of stock solution (µL)
10 ml                           100 ml
Chloramphenicol 100 15                                 150
Erythromycin 750 10                                 100
Kanamycin 50  5                                   50





Volume of stock solution (µL)
10 ml                            100 ml
Chloramphenicol 3 3                                      30
Erythromycin 1 10                                   100
Kanamycin 700 70                                   700
Spectinomycin 150 15                                   150
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III.Buffers and solutions:
1) PBS buffer (10X)
80 grams  NaCl
2 grams  KCl
2 grams  K phosphate monobasic
11.5 grams  Na phosphate dibasic heptahydrate
pH 7.2
2) TAE Buffer (10X)
48.8 grams  Tris Base
11.42 mL  Glacial acetic acid
2 mL   0.5M EDTA pH 8.0
q.s. to 1 Liter with ddH2O
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APPENDIX B: Protocols
I. Generation of In-Frame Deletion Strain
1. Once Erm resistant colonies are obtained (which have been grown at 
30°C) pick colonies and grow them in 10 ml of THY+Erm1 at 30°C.
2. Next morning, make freezer stocks of the overnight cultures and 
inoculate 10 µL of overnight cultures into 10 ml of THY+Erm1 and 
incubate at 39°C. This shift of temperature will select for the integration 
of the plasmid into the chromosome, as pJRS233 cannot replicate at 
39°C.
3. Next morning, inoculate 10 µL of overnight culture into 10 ml of THY
+Erm1 and incubate at 39°C. Passing twice at 39°C in presence of 
Erm1 ensures integration of the plasmid.
4. Next morning, inoculate 10 µL of overnight culture into 10 ml THY 
without Erm and incubate at 30°C. This temperature shift selects for 
the excision of the plasmid, which could leave either the wild type or 
deletion allele of the gene. 
5. Repeat step 4) twice. Three times passing of the cultures at 30°C 
without Erm is necessary to get sufficient percentage of Erm sensitive 
cells in the culture. 
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6. After the final passage, make freezer stock of 2 cultures and plate,  
and dilutions on THY agar in the absence of Erm, and incubate 
overnight at 30°C in an anaerobic conditions.
7. Pick colonies and replica-plate (by patching with sterile wooden sticks) 
on THY+ Erm1 and THY plates. Patch 100 colonies. Incubate 
overnight in anaerobic conditions at 30°C.
8. Grow up those patches which were Erm sensitive at 37°C and make 
freezer stocks and confirm chromosomal structure by PCR after 
chromosomal extraction, as these strains could have either wild type or 
deleted chromosomal structure. Test 10 colonies. If all the 10 colonies 
have the wild type genotype, try again from the beginning. 
9. Make freezer stock of wild type revertant as a control and another 
stock of settled down strains. 
II.  Isopropanol precipitation
1. Transfer the sample to an Eppendorf tube. Sample volume in a tube 
should be less than 800 µL. if sample volume is over 800 µL split in 
two tubes. 
2. Add 1/10 volume of 3M Sodium Acetate solution (pH5.2) to the sample.
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3. Add 70% of the final volume of room temperature isopropanol to the 
DNA solution and mix well.
4. Centrifuge the sample immediately at 10,000 – 15,000 x g for 1 hour at 
4°C.
5. Carefully decant the supernatant without disturbing the pellet.
6. Add 1 ml of 70% EtOH to a tube gently.
7. Centrifuge at 10,000 – 15,000 xg for 15 minutes at 4°C.
8. Carefully decant the supernatant without disturbing the pellet.
9. Remove the residual ethanol solution with a pipette very carefully.
10. Dry the pellet at 50°C for 5 – 20 minutes (depending on the size of the 
pellet). 
11. Add DW. Added amount of DDW depends on the final DNA 
concentration you want to get. Usually 50 µL is enough.
12. Tap the tubes vigorously to dissolve DNA for about 5 minutes per tube.
13. Examine DNA concentration by gel electrophoresis or nanodrop.
14. Store sample at -20°C.
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III.Electroporation of S. pyogenes
1. Prepare DNA
2. Prepare THY plates containing appropriate antibiotics.
3. Add 100 µL of filter sterilized 2M glycine solution to 10 ml TP medium 
and add appropriate antibiotic.
4. Inoculate S. pyogenes and incubate them overnight at 37°C.
5. Next morning, add 1 ml of filter sterilized 2M glycine solution to 200 ml 
of TP medium plus appropriate antibiotic.
6. Take out 2 ml for blanks (1 ml per cuvette) for spectrophotometry and 
add 2 ml of overnight culture to 98 ml of TP+ glycine and add 
appropriate antibiotic.
7. Incubate the culture at 37°C until the culture reaches OD600=0.24. 
8. Distribute cultures into 4 tubes of 50 ml falcon tubes.
9. Harvest cells by centrifugation (7,000 x g for 10 minutes at room 
temperature). Resuspend total cell pellets in 4 ml of the supernatant.
10. Incubate cells at 43°C for 9 minutes. 
11. Add 6 ml of 15% glycerol solution and centrifuge the cells (7,000 x g) 
for 10 minutes at room temperature. 
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12. Discard the supernatant and wash the cells three times with 10 ml of 
15% glycerol solution.
13. Remove the supernatant as much as possible.
14. Resuspend the cell pellet in 800 µL of 15% glycerol solution.
15. Keep competent cells at room temperature until electroporation.
16. Place tubes of 10 ml of THY media and electroporator cuvettes on ice. 
17. Set the electroporator condition (Voltage: 2100 V, Capacitor: 25 µF, 
Resistance: 200 Ohms, electroporator cuvette: 2 mm).
18. Place DNA in an ice-cold 2 mm electroporator cuvette:
Suicide vectors: 10 – 20 µL
Shuttle vectors: 0.5 – 2 µL
Transposon vectors: 10 – 20 µL
pJRS233: 10 – 20 µL
19. Add 200 µL of competent cells into the cuvettes ad pipette up and 
down to mix well.
20. Give electric shock.
21. Immediately, remove cells from the cuvette and add the cells into the 
cold 10 ml THY media.
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22. Record the time constant.
23. Incubate cells for 30 minutes on ice, then 1 hour and 30 minutes at 
37°C. Dry the plates during this time.
24. Harvest cells by centrifugation (7,000 x g) for 10 minutes at room 
temperature and resuspend cells in 500 µL of THY medium.
25. Plate 100 µL of cells on each plate.
26. Incubate overnight at 37°C in anaerobic conditions.
IV. Electroporation of S. pyogenes with pJRS233 derivatives
1. Prepare pJRS233 using a Maxi prep kit (initial volume: 300 ml of 
overnight culture, final volume: 50-100 µL in DDW).
2. Prepare THY agar plates with no antibiotic (24 ml THY agar/plate)
3. Add 100 µL of filter sterilized 2M glycine solution to 10 mL of TP 
medium.
4. Inoculate S. pyogenes and grow overnight at 37°C.
5. Next morning, add 1 ml of filter sterilized 2M glycine solution to 100 
mL of TP medium.
6. Take blanks for spectrophotometry (2 mL) and add 2 mL of overnight 
culture to 98 mL of TP+Glycine medium containing proper antibiotic.
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7. Incubate the culture at 37°C until the culture reaches OD= ≈ 0.24. 
Usually it takes 2 hours for wild type.
8. Turn on the heat block containing a 15 ml tube block and set 
temperature at 43°C.
9. When the culture reaches OD= ≈0.24, distribute cultures into two 50 
mL falcon tubes and harvest cells by centrifugation (7,000 x g for 10 
minutes at 14°C).
10. Resuspend total cell pellets in 2 mL of the supernatant and transfer to 
a 15 mL falcon tube.
11. Incubate cells at 43°C for 9 minutes. Use the heat block.
12. Add 8 mL of 15% glycerol solution and centrifuge the cells (7,000 x g 
for 10 minutes at 14°C).
13. Discard the supernatant and wash the cells twice with 10 mL of 15% 
glycerol solution (centrifugation at 14°C).
14. During the final wash, place tubes of 10 mL of THY media and 
electroporator cuvettes on ice. The tube number are transformation 
number plus one (for negative control). The cuvette number is the 
same as the transformation number.
15. Remove supernatant as much as possible after the final wash.
16. Resuspend the cell pellet in 600 µL of 15% glycerol solution.
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17. Keep the competent cells at room temperature, not on ice. Perform a 
Electroporation as soon as possible. 
18. Set the electroporator (voltage: 2100V, Capacitor: 25µF, Resistance: 
200 Ω, electroporator cuvette: 2 mm).
19. Place DNA in an ice-cold 2 mm electroporator cuvette.
a. pJRS233 derivative: 10-20 µg
b. DNA concentration after Maxi-prep using 300 mL of 20-24 hrs 
culture: 3-4 µg/µL
20. Add 200 µL of competent cells into the cuvettes and pipette up and 
down to mix well.
21. Press the red button on the electroporator.
22. Immediately, remove cells from the cuvette and add the cells into the 
cold 10 mL THY media.
23. Record the time constant.
24. Incubate cells for 30 minutes on ice, then 1 hour in the 30°C incubator. 
You can dry the agar plates during this time if plates are not dry.
25. Harvest cells by centrifugation (7,000 x g for 10 minutes at room 
temperature) and resuspend cells in 300 µL of THY medium.
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26. Add 300 µL of cells to 15 mL of THY soft agar (cooled down to 43°C), 
mix gently and pour 3 mL of cells-soft agar mix onto a THY + Erm1 
plate.
27. Incubate the plates in an anaerobic jar at 30°C at least 2 hours and no 
more than 3 hours.
28. Remove the plates from the anaerobic jar. Overlay with an additional 3 
mL THY soft agar containing erythromycin (4 µg/mL)
29. Incubate plates at 30°C for 48 hours in an anaerobic jar.
V. E. coli transformation:
1. Thaw frozen Top10 competent cells on ice. 
2. To each Top10 cell aliquot add 1 – 200 ng of transforming DNA in a 
volume of 10 µL or less. For a ligate, use 10 µL (maximum amount). 
Include a positive control (the undigested vector for the cloning) and no 
DNA control.
3. Place cells on ice for 30 minutes.
4. Heat shock cells for 30 seconds at 43°C.
5. Add 1 ml of LB broth to each tube and incubate at 37°C for one hour, 
shaking intermittently or in a 37°C shaker incubator.
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6. Dry agar plates.
7. Plate 200 µL of cells on selective agar plates (6 plates for 
transformation and 1 plate for control cells).
8. Incubate plates overnight at 37°C.
VI. Quantitation of S. pyogenes capsule:
1. Grow S. pyogenes overnight in 10 ml THY media with appropriate 
antibiotic.
2. Next morning, dilute cells to 10-5, 10-6, and 10-7 with sterile PBS buffer 
and plate 100 µL of cells on THY agar plates. Incubate the plates at 
37°C in anaerobic conditions. Make triplicate dilutions and place each 
set in a different jar (or as many as the temperature that will be tested)
3. 24 hours later, take out the jars and place one at 25°C (if more 
temperatures will be tested, then move each jar to each temperature) 
and save one jar for measurement at 37°C. Measure the capsule 
amount produced by the 37°C jar.
4. 4-5 hours later, measure the capsule amount produced by colonies on 
the plates incubated at 25°C.
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Capsule Quantitation using Stains-All reagent solution
Analyze in duplicate. Do not use PBS buffer in the Stains-All assay 
because it inhibits the reaction
5. 2X Stains-All reagent: 20 mg of Stains-All and 60 µL of glacial acetic 
acid in 50 mL of 50% formamide. Wrap the reagent bottle with foil 
because itʼs degraded by light. Store at 4°C. The reagent is effective 
within a month.
6. Take colonies carefully using a spatula and place this colony into a 
tube with 10 ml of DDW.  Duplicate the samples.
7. Vortex the tubes about 1 minute to resuspend cells and capsule.
8. Take 100 µL of the resuspension and dilute it in 900 µL of PBS buffer. 
Save for later serial dilution and plating. This will be the first tube of the 
serial dilution.
9. Centrifuge the 10 ml tubes to precipitate cells (6,000 x g) for 10 
minutes at room temperature.
10. Take 500 µL of supernatant into a spectrophotometry cuvette.
11. Mix with 500 µL of 2X Stains-all reagent.
12. Prepare hyaluronic acid solutions for a standard curve. Add 1 µL, 2 µL, 
3 µL, 4 µL and 5 µL of 1 mg/ml hyaluronic acid in 500 µL of DDW in a 
spectrophotometer cuvette. Mix the solution very well with a P1000 
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pippetman. This mixing step is very important because hyaluronic acid 
does not dissolve in the Stains-all reagent. Add 500 µL of the Stains-all 
reagent to each cuvette and mix well.
13. Prepare blanks with 500 µL of DDW mixed with 500 µL of Stains-all. 
14. Measure OD640
15. Dilute resuspended cells to 10-3, 10-4 and 10-5 with PBS buffer and 
plate 100 µL of cells on THY agar plates. Make the dilution and plating 
in duplicate. Next morning count appropriately spread colonies and 
calculate cell concentration (cell number/ml). 
16. Using the standard curve and cell concentration, calculate the amount 
of capsule produced per CFU.
17. 5 hours later, measure the capsule amount produced by colonies on 
the plates at room temperature the same way it was done before, 
make dilutions, plate and then count colonies to calculate cell 
concentration and capsule production. 
VII. Storing cells at -80°C freezer
1. Grow cells overnight in THY media with antibiotics if needed.
2. Transfer 0.7 mL of culture into a cryogenic tube and add 0.3 mL of 
80% glycerol solution. Mix well.
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3. Label the tube and store at -80°C. 
VIII. Plasmid extraction 
All plasmids were propagated in E. coli Top10 cells and extracted using 
Biotech Gerard Maxi Prep Kit according to manufacturerʼs protocol, 
except that final volume was 2 mL per sample.  Initial volume: 300 mL 
of LB broth.
IX. DNA Purification for PCR products
PCR products were purified using Qiagen PCR Purification Kit 
following the protocol provided by the manufacturer. 
X. Preparation of Chromosome of S. pyogenes with Sigma column
1. Grow 10 ml of overnight culture in THY broth with 100 µL of 20mM 
glycine and add appropriate antibiotic if necessary. 
2. Harvest cells by centrifugation at 7,000 rpm for 10 minutes.
3. Wash twice with 3 ml of TE buffer.
4. Add 200 µL of lysozyme (100 mg/µL), 2 µL of mutanolysin (100 µ/
µL), 80 µL of RNAse and 520 µL of Gram positive solution. 
5. Incubate 1 hour at 37°C with intermittent shaking.
99
6. Follow the remaining steps provided by the manufacturer.
XI. Preparation of E. coli competent cells
1. Grow Top10 cells in 10 mL of LB broth at 37°C overnight.
2. Dilute 1 mL of cells into 200 mL of LBB in a 500 mL flask.
3. Make solutions and keep them on ice.
4. Grow cells with vigorous shaking until they reach 10-8 cells/mL. It 
takes approximately 2 hours.
5. Divide 200 mL culture into four 50 mL conical tubes.
6. Harvest cells at 5,000 x g for 5 minutes at 4°C. From this point on, 
cells must be kept ice cold.
7. Gently resuspend each pellet in 10 mL ice cold, sterile solution I.
8. Recover cells by centrifugation at 5,000 x g, 5 minutes, 4°C.
9. Discard supernatant. Gently resuspend each pellet in 10 mL of 
solution II. Pipette up and down. Do not vortex.
10. Place tubes on ice for 15 minutes.
11. Recover cells by centrifugation, 5,000 x g, 5 minutes, 4°C. gently 
resuspend all pellets in 10 mL of solution II containing 10% (v/v) 
glycerol.
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12. Divide cells in 200 µL aliquots in eppendorf tubes (approximately 50 
tubes) and freeze at -80°C.
Solution I 10 mM MOPS (KOH) pH 7.0
10 mM RbCl
Solution II 100 mM MOPS (KOH) pH 6.5
50 mM CaCl2
10 mM RbCl
Stock solutions .1 M MOPS pH 7.0
.1 M RbCl
1.0 M MOPS pH 6.5
0.5 M CaCl2
Solution I 32 mL ddH2O
4 mL 0.1M MOPS pH 7.0
4 mL 0.1 RbCl
Solution II 35 mL ddH2O
5 mL 1.0 M MOPS pH 6.5
5 mL 0.1 M RbCl
5 mL 0.5 M CaCl2
Solution II containing 10% 
glycerol
10 mL solution II
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